ENDRA Life Sciences Inc. (NDRA)
USD 4.62
(0.87%)
USD 4.62
(0.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -10.06 Million USD | 23.79% |
| 2022 | -13.2 Million USD | -17.97% |
| 2021 | -11.18 Million USD | 6.49% |
| 2020 | -11.96 Million USD | 23.07% |
| 2019 | -15.55 Million USD | -58.78% |
| 2018 | -9.79 Million USD | -82.19% |
| 2017 | -5.37 Million USD | -93.74% |
| 2016 | -2.77 Million USD | -21.77% |
| 2015 | -2.27 Million USD | -4.51% |
| 2014 | -2.18 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.22 Million USD | 19.69% |
| 2024 Q1 | -2.77 Million USD | -90.18% |
| 2023 FY | -10.06 Million USD | 23.79% |
| 2023 Q1 | -2.94 Million USD | 9.79% |
| 2023 Q4 | -1.45 Million USD | 52.93% |
| 2023 Q3 | -3.1 Million USD | -21.26% |
| 2023 Q2 | -2.55 Million USD | 13.2% |
| 2022 Q2 | -3.61 Million USD | 100.0% |
| 2022 Q3 | -3.46 Million USD | 4.08% |
| 2022 FY | -13.2 Million USD | -17.97% |
| 2022 Q1 | -2858.2 Billion USD | -92062524.02% |
| 2022 Q4 | -3.26 Million USD | 5.7% |
| 2021 Q2 | -3.19 Million USD | -40.97% |
| 2021 FY | -11.18 Million USD | 6.49% |
| 2021 Q1 | -2.26 Million USD | -0.82% |
| 2021 Q4 | -3.1 Million USD | -16.79% |
| 2021 Q3 | -2.65 Million USD | 16.91% |
| 2020 Q4 | -2.25 Million USD | 30.92% |
| 2020 FY | -11.96 Million USD | 23.07% |
| 2020 Q3 | -3.25 Million USD | -12.59% |
| 2020 Q2 | -2.89 Million USD | 12.91% |
| 2020 Q1 | -3.32 Million USD | 30.91% |
| 2019 Q2 | -2.33 Million USD | 15.07% |
| 2019 Q1 | -2.74 Million USD | -16.2% |
| 2019 FY | -15.55 Million USD | -58.78% |
| 2019 Q4 | -4.8 Million USD | -40.89% |
| 2019 Q3 | -3.41 Million USD | -46.23% |
| 2018 Q4 | -2.36 Million USD | 14.25% |
| 2018 Q3 | -2.75 Million USD | -49.37% |
| 2018 Q2 | -1.84 Million USD | 34.63% |
| 2018 Q1 | -2.82 Million USD | -23.13% |
| 2018 FY | -9.79 Million USD | -82.19% |
| 2017 FY | -5.37 Million USD | -93.74% |
| 2017 Q1 | -741.62 Thousand USD | -7.97% |
| 2017 Q4 | -2.29 Million USD | -152.46% |
| 2017 Q2 | -1.43 Million USD | -93.06% |
| 2017 Q3 | -908.9 Thousand USD | 36.52% |
| 2016 Q2 | -729.11 Thousand USD | -92.14% |
| 2016 Q4 | -686.87 Thousand USD | 29.9% |
| 2016 Q1 | -379.47 Thousand USD | 17.28% |
| 2016 Q3 | -979.89 Thousand USD | -34.4% |
| 2016 FY | -2.77 Million USD | -21.77% |
| 2015 FY | -2.27 Million USD | -4.51% |
| 2015 Q4 | -458.73 Thousand USD | 15.2% |
| 2015 Q2 | -844.57 Thousand USD | -49.82% |
| 2015 Q3 | -540.98 Thousand USD | 35.95% |
| 2015 Q1 | -563.74 Thousand USD | 0.0% |
| 2014 FY | -2.18 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 95.673% |
| Prenetics Global Limited | -62.72 Million USD | 83.961% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -549.887% |
| CareDx, Inc | -190.28 Million USD | 94.713% |
| Exact Sciences Corporation | -204.14 Million USD | 95.072% |
| Exagen Inc. | -23.68 Million USD | 57.532% |
| Inotiv, Inc. | -105.14 Million USD | 90.432% |
| Guardant Health, Inc. | -479.44 Million USD | 97.902% |
| Biodesix, Inc. | -52.14 Million USD | 80.708% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -282.658% |
| Precipio, Inc. | -5.85 Million USD | -71.882% |
| iSpecimen Inc. | -11.09 Million USD | 9.363% |
| Natera, Inc. | -434.8 Million USD | 97.686% |
| Aspira Women's Health Inc. | -16.69 Million USD | 39.723% |
| Standard BioTools Inc. | -74.65 Million USD | 86.525% |
| 23andMe Holding Co. | -666.7 Million USD | 98.491% |
| Castle Biosciences, Inc. | -57.46 Million USD | 82.494% |
| Personalis, Inc. | -108.29 Million USD | 90.71% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 88.63% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -1.138% |
| OpGen, Inc. | -32.66 Million USD | 69.205% |
| T2 Biosystems, Inc. | -50.07 Million USD | 79.91% |
| Myriad Genetics, Inc. | -112 Million USD | 91.018% |
| ICON Public Limited Company | 612.33 Million USD | 101.643% |
| NeoGenomics, Inc. | -87.96 Million USD | 88.564% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -549.887% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 101.191% |
| RadNet, Inc. | 3.04 Million USD | 430.494% |
| MDxHealth SA | -43.1 Million USD | 76.658% |
| Psychemedics Corporation | -4.15 Million USD | -142.182% |
| Illumina, Inc. | -1.16 Billion USD | 99.133% |
| Check-Cap Ltd. | -17.56 Million USD | 42.735% |
| Twist Bioscience Corporation | -208.72 Million USD | 95.18% |
| DarioHealth Corp. | -59.42 Million USD | 83.071% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 94.006% |
| Sera Prognostics, Inc. | -36.24 Million USD | 72.241% |
| OPKO Health, Inc. | -188.86 Million USD | 94.673% |
| Medpace Holdings, Inc. | 282.81 Million USD | 103.557% |
| Neogen Corporation | -9.42 Million USD | -6.785% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | 0.95% |
| Prenetics Global Limited | -62.72 Million USD | 83.961% |
| Mainz Biomed B.V. | -26.29 Million USD | 61.742% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -26.751% |
| Trinity Biotech plc | -24.01 Million USD | 58.114% |
| Neuronetics, Inc. | -30.18 Million USD | 66.676% |
| Sotera Health Company | 51.37 Million USD | 119.582% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -26.751% |